Pharma-Bio Serv (PBSV) Gross Margin (2010 - 2026)
Pharma-Bio Serv's (PBSV) quarterly Gross Margin came in at 33.37% in Q2 2026, down 50.0% on a YoY basis from 66.75% in Q2 2025, and up 6.02% quarter-over-quarter from 31.48% in Q1 2026.
Powered by 
Analysis
Pharma-Bio Serv (PBSV) Gross Margin (2010 - 2026) Analysis & Trends
Pharma-Bio Serv (PBSV) has reported Gross Margin for 16 consecutive years, with 33.37% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Gross Margin fell 50.0% year-over-year to 33.37%; the trailing twelve-month figure through Apr 2026 stood at 32.35% (up 176.0% YoY), and the FY2025 full-year result was 32.33%, up 587.0% from the prior year.
- Gross Margin climbed to 33.37% in Q2 2026 per PBSV's latest filing, from 31.48% in the prior quarter.
- Across five years, Gross Margin topped out at 34.84% in Q4 2025 and bottomed at 22.5% in Q1 2024.
- Historically, Gross Margin has averaged 28.83% across 5 years, with a median of 29.26% in 2023.
- The sharpest annual moves came in 2024 and 2025: Gross Margin slumped 759 bps in 2024, then surged 858 bps in 2025.
- Over 5 years, Gross Margin stood at 23.9% in 2022, then climbed by 8 bps to 25.84% in 2023, then increased by 21 bps to 31.14% in 2024, then climbed by 12 bps to 34.84% in 2025, then decreased by 4 bps to 33.37% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 33.37%, 31.48%, and 34.84% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Accenture | 124.62 Bn | 115.58 Bn | 6.13 Bn | 32.77% |
| 2 | UL Solutions | 14.92 Bn | 14.51 Bn | 417.00 Mn | 51.10% |
| 3 | Gartner | 11.76 Bn | 10.28 Bn | 1.19 Bn | 70.95% |
| 4 | Tetra Tech | 9.19 Bn | 8.96 Bn | 243.21 Mn | 18.59% |
| 5 | Booz Allen Hamilton Holding | 8.76 Bn | 8.22 Bn | 1.46 Bn | 52.29% |
| 6 | Genpact | 6.27 Bn | 5.75 Bn | 490.34 Mn | 36.50% |
| 7 | Korn Ferry | 4.28 Bn | 3.15 Bn | 685.99 Mn | 89.29% |
| 8 | Fti Consulting | 4.20 Bn | 4.04 Bn | 316.27 Mn | 31.84% |
| 9 | Grand Canyon Education | 4.01 Bn | 3.73 Bn | 204.08 Mn | 77.29% |
| 10 | Pharma-Bio Serv | 12.37 Mn | 3.89 Mn | 902,041.00 | 33.37% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | 33.37% |
| Jan 31, 2026 | 31.48% |
| Oct 31, 2025 | 34.84% |
| Jul 31, 2025 | 29.25% |
| Apr 30, 2025 | 33.87% |
| Jan 31, 2025 | 31.08% |
| Oct 31, 2024 | 31.14% |
| Jul 31, 2024 | 26.28% |
| Apr 30, 2024 | 26.01% |
| Jan 31, 2024 | 22.50% |
| Oct 31, 2023 | 25.84% |
| Jul 31, 2023 | 33.86% |
| Apr 30, 2023 | 29.51% |
| Jan 31, 2023 | 29.26% |
| Oct 31, 2022 | 23.90% |
| Jul 31, 2022 | 27.49% |
| Apr 30, 2022 | 24.48% |
| Jan 31, 2022 | 24.80% |
| Oct 31, 2021 | 26.78% |
| Jul 31, 2021 | 25.16% |